País: Suecia
Idioma: sueco
Fuente: Läkemedelsverket (Medical Products Agency)
bivalirudin
Cipla Europe NV
B01AE06
bivalirudin
250 mg
Pulver till koncentrat till injektions-/infusionsvätska, lösning
bivalirudin 250 mg Aktiv substans; mannitol Hjälpämne
Receptbelagt
Förpacknings: Injektionsflaska, 1 st; Injektionsflaska, 10 x 1 st
Avregistrerad
2016-08-24
PACKAGE LEAFLET: INFORMATION FOR THE USER BIVALIRUDIN CIPLA 250 MG POWDER FOR CONCENTRATE FOR SOLUTION FOR INJECTION/ INFUSION bivalirudin READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor. If you get any side effects talk to your doctor. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Bivalirudin Cipla is and what it is used for 2. What you need to know before you use Bivalirudin Cipla 3. How to use Bivalirudin Cipla 4. Possible side effects 5. How to store Bivalirudin Cipla 6. Contents of the pack and other information 1. WHAT BIVALIRUDIN CIPLA IS AND WHAT IT IS USED FOR Bivalirudin Cipla contains a substance called bivalirudin which is an antithrombotic medicine. Antithrombotics are medicines which prevent the formation of blood clots (thrombosis). Bivalirudin Cipla is used to treat patients : with chest pain due to heart disease (acute coronary syndromes - ACS); who are having surgery to treat blockages in their blood vessels (angioplasty and/or percutaneous coronary intervention - PCI). 2. WHAT YOU NEED TO KNOW BEFORE YOU USE BIVALIRUDIN CIPLA DO NOT USE BIVALIRUDIN CIPLA if you are allergic to bivalirudin or any of the other ingredients of this medicine (listed in section 6) or hirudins (other blood thinning medicines); if you have, or have recently had, any bleeding from your stomach, intestines, bladder or other organs, for example, if you have noticed abnormal blood in your stools or urine (except from menstrual bleeding); if you have, or have had, difficulty with your blood clotting (a low platelet count); if you have severe high blood pressure; if you have an infection of the heart tissue; if you have severe kidney problems or if you need kidney dialysis. Check with the doctor if you are not sure. WARNINGS AND PRECAUTIONS Leer el documento completo
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Bivalirudin Cipla 250 mg powder for concentrate for solution for injection/infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains 250 mg bivalirudin After reconstitution 1 ml contains 50 mg bivalirudin. After dilution 1 ml contains 5 mg bivalirudin. For the full list of excipients, see section 6.1 3. PHARMACEUTICAL FORM Powder for concentrate for solution for injection/infusion White to off white lyophilized powder/cake. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Bivalirudin Cipla is indicated as an anticoagulant in adult patients undergoing percutaneous coronary intervention (PCI), including patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary PCI. Bivalirudin Cipla is also indicated for the treatment of adult patients with unstable angina/non-ST segment elevation myocardial infarction (UA/NSTEMI) planned for urgent or early intervention. Bivalirudin Cipla should be administered with acetylsalicylic acid and clopidogrel. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Bivalirudin Cipla should be administered by a physician experienced in either acute coronary care or in coronary intervention procedures. Posology _Patients undergoing PCI, including patients with ST-segment elevation myocardial infarction _ _(STEMI) undergoing primary PCI_ The recommended dose of bivalirudin for patients undergoing PCI is an intravenous bolus of 0.75 mg/kg body weight followed immediately by an intravenous infusion at a rate of 1.75 mg/kg body weight/hour for at least the duration of the procedure. The infusion of 1.75 mg/kg body weight/hour may be continued for up to 4 hours post-PCI and at a reduced dose of 0.25 mg/kg body weight/hour for an additional 4-12 hours as clinical necessary. In STEMI patients the infusion of 1.75 mg/kg body weight/hour should be continued for up to 4 hours post-PCI and continued at a reduced dose of 0.25 mg/kg body weight/hour for an additional 4 – 12 hours as clinically necessary ( Leer el documento completo